Looking forward to presenting prelim results of our phase 1 study of intravesical Fc-engineered anti-CD40 agonistic antibody in NMIBC at AACR. Amazing MSK/RU collaboration led by @bbmdms Jonathan Rosenberg MD moving from the bench to the clinic! #AACR24
abstractsonline.com/pp8/#!/20272/p…

Together with Alliance for Clinical Trials in Oncology, we're pleased to announce the the launch of Alliance A032103 (MODERN), a randomized, phase II/III, biomarker-integrated trial. ow.ly/ihAF50R5IT8

Very happy to see this in print! Congratulations to all involved in this transformative effort, and to the patients who may benefit from this combination therapy.

This trial will answer several important questions- do we need to escalate therapy to get better outcomes in the highest risk patients, and can we de-escalate in those who are lower risk. Matt Galsky Andrea Apolo, M.D. Tom Powles Guru P. Sonpavde, MD Tian Zhang, MD, MHS

EV301👉HRQoL with EV was maintained, and deterioration in HRQoL was delayed with EV in comparison to chemotherapy. 👉Better results with EV were reported for some scales ⁦Jonathan Rosenberg MD⁩ ⁦Tom Powles⁩ europeanurology.com/article/S0302-…

We have a two year position for early career investigator focused on gastroesophageal cancer.
Details below
careers.mskcc.org/vacancies/2024…

Exciting risk-adapted trial for adjuvant therapy in urothelial cancer. Able to be opened across the NCTN program!

Big news for bladder cancer in US!
“On December 15, 2023, the Food and Drug Administration (FDA) approved enfortumab vedotin-ejfv in combination with pembrolizumab for patients with locally advanced or metastatic urothelial cancer (la/mUC).”

Can’t agree more!

Very excited to announce our work on understanding the contributions of Fc gamma receptors (FcgR) to the antitumor activity of CD47 antibodies, and Fc-engineering as a strategy to enhanced the activity of this immunotherapy. Out today in
Cancer Cell:
cell.com/cancer-cell/fu…

Lots of great candidates that i am fortunate to know personally, including Dr. Small, Dr. Rathmell, and, of course my great friend and former colleague, Toni Choueiri, MD. Its a great opportunity for GU Oncology to have so many outstanding candidates.
old-prod.asco.org/about-asco/asc…

Congratulations to Dr. Guercio- I look forward to continuing our collaborations!
kidneycancer.org/stories/qa-bre…

Congratulations to Dr. Carlo- very well deserved!
kidneycancer.org/stories/qa-mar…

Voting for the ASCO Election is now open. I am honored to be running as one of the candidates for the Board of Directors Undesignated Member seats.

Visit asco.org/election to learn more about the candidates and place your votes!

ASCO OncoAlert Oncology Brothers Dana-Farber

Post #ESMO23 (and pre #SABCS23 #ASH23 ) we have to digest a lot of data! Join us for 3 days of CME with Benjamin Levy Jonathan Rosenberg MD Joshua Sabari, MD Stephen V Liu, MD Komal Jhaveri Amer Zeidan MBBS,MHS ‏عامر زيدان

Going to take some📝 from Aaron Goodman - “Papa Heme” and Mark Lewis for Social Media advantages.

Very important IIT- biomarker analyses will help us understand the contribution of EV and pembro to the outstanding treatment results in urothelial carcinoma. Memorial Sloan Kettering Cancer Center MSK Department of Medicine Hikmat Al Ahmadie Benjamin D. Greenbaum David B. Solit, MD Miami Cancer Institute Research Tian Zhang, MD, MHS Andrea Apolo, M.D. Tom Powles

On the heels of EV-302 data in 1st line UC at #ESMO2023 - we are actively investigating EV + pembro prior to surgery for LN + bladder cancer.

Open Memorial Sloan Kettering Cancer Center UTSW Simmons Cancer Center Miami Cancer Institute Research

ClinicalTrials.gov: bit.ly/3tOvm48
MSK link: bit.ly/3Fp4DxQ

An eloquent discussion from KSridhar on periop trials, highlighting LN positive #bladdercancer as opportunity & upcoming Alliance for Clinical Trials in Oncology #MODERN trial for adjuvant #bladdercancer . Great discussion on endpoints. ESMO - Eur. Oncology #ESMO23 OncoAlert

EV-302 data changes the game in metastatic UC. Congrats to Tom Powles for a well conducted study and great presentation, and to the entire EV-302 study team Gopa Iyer. Congrats to Andrea Apolo, M.D. for her insightful discussion. Memorial Sloan Kettering Cancer Center Michiel van der Heijden Bladder Cancer Advocacy Network

Livestream sessions for #UromigosLive 2023: 1st line bladder cancer Jonathan Rosenberg MD Matt Galsky Shilpa Gupta, Tom Powles and 1st line RCC with Brian Rini, MD, Drs. Atkins and McDermott.

UROMIGOS cup Semi-finals and Final. Livestream links to follow and on Uromigos.org!